Login Register Cart 0
Review Article

口服补体因子D抑制剂Danicopan（ACH-4471）的发现和开发

卷 27, 期 25, 2020

页: [4165 - 4180] 页: 16

弟呕挨: 10.2174/0929867326666191001130342

价格: $65

摘要

补体在我们对入侵微生物的天然免疫防御中起着至关重要的作用。但是，补体激活过度或宿主细胞激活控制不足可能与几种慢性疾病有关。补体因子D（CFD）是补体替代途径（AP）激活和扩增所必需的，是一种特异性丝氨酸蛋白酶，可裂解其独特的底物补体因子B（CFB），并与活化形式的补体成分3（ C3），以生成AP C3转化酶C3（H2O）Bb和C3bBb。这些转化酶是AP激活后引发效应子应答的重要组成部分，它们还为补体的经典途径（CP）和凝集素途径（LP）都提供了强大的扩增环。由于CP或LP的激活均不需要CFD，因此选择性CFD抑制为调节补体活性提供了一种有益的治疗方法，使CP和LP激活后保留了完整的效应子功能，因此比其他补体具有较低的细菌感染风险导向的方法。这篇综述提供了关于CFD抑制剂的最新信息，这些抑制剂已从显示出较差的选择性的不可逆小分子演变为显示出优异的选择性和效能的可逆小分子和单克隆抗体。可逆小分子抑制剂danicopan_（ACH-4471）最近作为有前途的治疗候选药物出现。介绍了其发现，临床前药理学，健康志愿者的1期临床研究以及阵发性夜间血红蛋白尿（PNH）患者的2期临床研究的概述。

关键词: 补体，替代途径，补体因子D，口服抑制剂，danicopan，_ACH-4471，PNH。

« Previous Next »
[1]
Pekna, M.; Nilsson, L.; Nilsson-Ekdahl, K.; Nilsson, U.R.; Nilsson, B. Evidence for iC3 generation during cardiopulmonary bypass as the result of blood-gas interaction. Clin. Exp. Immunol., 1993, 91(3), 404-409.
[http://dx.doi.org/10.1111/j.1365-2249.1993.tb05916.x] [PMID: 8443963]
[2]
Harboe, M.; Garred, P.; Karlstrøm, E.; Lindstad, J.K.; Stahl, G.L.; Mollnes, T.E. The down-stream effects of mannaninduced lectin complement pathway activation depend quantitatively on alternative pathway amplification. Mol. Immunol., 2009, 47(2-3), 373-380.
[http://dx.doi.org/10.1016/j.molimm.2009.09.005] [PMID: 19800125]
[3]
Harboe, M.; Ulvund, G.; Vien, L.; Fung, M.; Mollnes, T.E. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin. Exp. Immunol., 2004, 138(3), 439-446.
[http://dx.doi.org/10.1111/j.1365-2249.2004.02627.x] [PMID: 15544620]
[4]
Podos, S.D.; Agarwal, A.; Huang, M.; Factor, D. Complement FactsBook, 2nd ed; LindaVersteeg-Buschman;Elsevier Science B: United-Kingdom, 2018, pp. 117-126.
[5]
Volanakis, J.E.; Narayana, S.V. Complement factor D, a novel serine protease. Protein Sci., 1996, 5(4), 553-564.
[http://dx.doi.org/10.1002/pro.5560050401] [PMID: 8845746]
[6]
Fearon, D.T.; Austen, K.F.; Ruddy, S. Properdin factor D: characterization of its active site and isolation of the precursor form. J. Exp. Med., 1974, 139(2), 355-366.
[http://dx.doi.org/10.1084/jem.139.2.355] [PMID: 4855753]
[7]
Cole, L.B.; Chu, N.; Kilpatrick, J.M.; Volanakis, J.E.; Narayana, S.V.; Babu, Y.S. Structure of diisopropyl fluorophosphate-inhibited factor D. Acta Crystallogr. D Biol. Crystallogr., 1997, 53(Pt 2), 143-150.
[http://dx.doi.org/10.1107/S0907444996012991] [PMID: 15299948]
[8]
Narayana, S.V.; Carson, M.; el-Kabbani, O.; Kilpatrick, J.M.; Moore, D.; Chen, X.; Bugg, C.E.; Volanakis, J.E.; DeLucas, L.J. Structure of human factor D. A complement system protein at 2.0 A resolution. J. Mol. Biol., 1994, 235(2), 695-708.
[http://dx.doi.org/10.1006/jmbi.1994.1021] [PMID: 8289289]
[9]
Kam, C.M.; Oglesby, T.J.; Pangburn, M.K.; Volanakis, J.E.; Powers, J.C. Substituted isocoumarins as inhibitors of complement serine proteases. J. Immunol., 1992, 149(1), 163-168.
[PMID: 1607651]
[10]
Jing, H.; Babu, Y.S.; Moore, D.; Kilpatrick, J.M.; Liu, X.Y.; Volanakis, J.E.; Narayana, S.V. Structures of native and complexed complement factor D: implications of the atypical His57 conformation and self-inhibitory loop in the regulation of specific serine protease activity. J. Mol. Biol., 1998, 282(5), 1061-1081.
[http://dx.doi.org/10.1006/jmbi.1998.2089] [PMID: 9753554]
[11]
Cole, L.B.; Kilpatrick, J.M.; Chu, N.; Babu, Y.S. Structure of 3,4-dichloroisocoumarin-inhibited factor D. Acta Crystallogr. D Biol. Crystallogr., 1998, 54(Pt 5), 711-717.
[http://dx.doi.org/10.1107/S0907444997010457] [PMID: 9757085]
[12]
Szalai, A.J.; Digerness, S.B.; Agrawal, A.; Kearney, J.F.; Bucy, R.P.; Niwas, S.; Kilpatrick, J.M.; Babu, Y.S.; Volanakis, J.E. The Arthus reaction in rodents: species-specific requirement of complement. J. Immunol., 2000, 164(1), 463-468.
[http://dx.doi.org/10.4049/jimmunol.164.1.463] [PMID: 10605043]
[13]
Fujii, S.; Hitomi, Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim. Biophys. Acta, 1981, 661(2), 342-345.
[http://dx.doi.org/10.1016/0005-2744(81)90023-1] [PMID: 6271224]
[14]
Ikari, N.; Sakai, Y.; Hitomi, Y.; Fujii, S. New synthetic inhibitor to the alternative complement pathway. Immunology, 1983, 49(4), 685-691.
[PMID: 6553561]
[15]
Tomioka, N.S.Y.; Itai, A. The refined crystal structure of the complex formed by bovine trypsin and p-guanidinobenzoate at 2.06 A resolution. FEBS Lett., 1989, 1, 153-155.
[http://dx.doi.org/10.1016/0014-5793(89)81638-2]
[16]
Narayana, S.V.B.Y.S.; Volanakis, J.E. Contemporary Immunology; Humana Press Inc.: Totowa, NJ, 2000.
[17]
Johnson, D.S.; Weerapana, E.; Cravatt, B.F. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. Future Med. Chem., 2010, 2(6), 949-964.
[http://dx.doi.org/10.4155/fmc.10.21] [PMID: 20640225]
[18]
Katschke, K.J., Jr; Wu, P.; Ganesan, R.; Kelley, R.F.; Mathieu, M.A.; Hass, P.E.; Murray, J.; Kirchhofer, D.; Wiesmann, C.; van Lookeren Campagne, M. Inhibiting alternative pathway complement activation by targeting the factor D exosite. J. Biol. Chem., 2012, 287(16), 12886-12892.
[http://dx.doi.org/10.1074/jbc.M112.345082] [PMID: 22362762]
[19]
Loyet, K.M.; Good, J.; Davancaze, T.; Sturgeon, L.; Wang, X.; Yang, J.; Le, K.N.; Wong, M.; Hass, P.E.; van Lookeren Campagne, M.; Haughney, P.C.; Morimoto, A.; Damico-Beyer, L.A.; DeForge, L.E. Complement inhibition in cynomolgus monkeys by anti-factor d antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration. J. Pharmacol. Exp. Ther., 2014, 351(3), 527-537.
[http://dx.doi.org/10.1124/jpet.114.215921] [PMID: 25232192]
[20]
Roche Press Release. Available at:https://www.roche.com/media/store/releases/med-cor-2017-09-08b.htm (Accessed March 11, 2018).
[21]
Roche Development Pipeline Update. Available at:https://www.roche.com/dam/jcr:77aa35dc-feef-427b-b9e3-befd9e735d2e/en/irp180201-annex.pdf (Accessed March 11, 2018)
[22]
Rawlings, ND.; Salvesen, G. Handbook of proteolytic enzymes. In: Academic press, 3rd ed; , 2013; 135, pp. (2)2841-2848.
[23]
Forneris, F.; Ricklin, D.; Wu, J.; Tzekou, A.; Wallace, R.S.; Lambris, J.D.; Gros, P. Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science, 2010, 330(6012), 1816-1820.
[http://dx.doi.org/10.1126/science.1195821] [PMID: 21205667]
[24]
Pais, G.; Hashimoto, A.; Gadhachanda, V.R.; Wang, Q.; Chen, D.; Wang, X.; Agarwal, A.; Deshpande, M.; Phadke, A. Alkyne compounds for treatment of complement mediated disorders., W.O. 2015130784A1. 2015.
[25]
Wang, Q.; Gadhachanda, V.R.; Pais, G.; Hashimoto, A.; Chen, D.; Wang, X.; Agarwal, A.; Deshpande, M.; Phadke, A.; Wiles, J.A. Amide compounds for treatment of complement mediated disorders., W.O. 20015/130795A1. 2015.
[26]
Gadhachanda, V.R.; Hashimoto, A.; Pais, G.; Wang, Q.; Chen, D.; Wang, X.; Agarwal, A.; Deshpande, M.; Wiles, J. A.; Phadke, A. Amino compounds for treatment of complement mediated disorders, W.O. 2015130806A1. 2015.
[27]
Gadhachanda, V.R; Pais, G.; Hashimoto, A.; Wang, Q.; Chen, D.; Wang, X.; Agarwal, A.; Deshpande, M.; Phadke, A.; Wiles, J. A. Carbamate, ester, and ketone compounds for treatment of complement mediated disorders, W.O.2015130830A1. 2015.
[28]
Gadhachanda, V.R.; Wang, Q.; Pais, G.; Hashimoto, A.; Chen, D.; Wang, X.; Agarwal, A.; Deshpande, M.; Wiles, J. A.; Phadke, A. Aryl, heteroaryl, and heterocyclic compounds for treament of complement mediated disorders, W.O. 2015130838A1. 2015.
[29]
Wiles, J.A.; Hashimoto, A.; Gadhachanda, V.R.; Pais, G.; Wang, Q.; Chen, D.; Wang, X.; Agarwal, A.; Deshpande, M.; Phadke, A. Phosphonate compounds for treatment of complement medi-ated disorders., W.O. 2015130845A1. 2015.
[30]
Gadhachanda, V.R.; Pais, G.; Hashimoto, A.; Wang, Q.; Chen, D.; Wang, X.; Agarwal, A.; Deshpande, M.; Phadke, A.; Wiles, J. A. Ether Compounds for treatment of complement mediated disorders., W.O. 2015130842A2. 2015.
[31]
Phadke, A.; Wang, X.; Chen, D.; Hashimoto, A.; Gadhachanda, V.R.; Pais, G.; Wang, X.; Agarwal, A.; Deshpande, M.; Wiles, J. A. Compounds for treatment of complement mediated disorders.., W.O. 2015130854A12015.
[32]
Altmann, E.; Hommel, U.; Lorthiosis, E.L.J.; Maibaum, J.K.; Ostermann, N.; Quancard, J.; Randl, S.A.; Simic, O.; Vulpetti, A.; Rogel, O. Indole compounds or analogues thereof useful for the treat-ment of age-related macular degeneration (AMD)., W.O. 2012093101A1. 2012.
[33]
Altmann, E.; Hommel, U.; Lorthiosis, E.L.J.; Maibaum, J.K.; Termann, N.; Quancard, J.; Randl, S.A.; Vulpetti, A.; Rogel, O. Complement pathway modulators and uses thereof., W.O. 2014002051A2. 2014.
[34]
Flohr, S.; Hommel, U.; Lorthiosis, E.L.J.; Mabaum, J.K.; Ostermann, N.; Randl, S. A.; Vulpetti, A.; Quancard, J. Pyrrolidine derivatives and their use as complement pathway modulators., W.O. 2014002052A1,. 2014.
[35]
Altmann, E.; Hommel, U.; Lorthiosis, E.L.J.; Maibaum, J.K.; Ostermann, N.; Randl, S.A.; Vulpetti, A.; Rogel, O. Pyrrolidine derivatives and their use as complement pathway modulators., W.O. 2014002053A1,. 2014.
[36]
Altmann, E.; Hommel, U.; Lorthiosis, E.L.J.; Maibaum, J.K.; Ostermann, N.; Quancard, J.; Randl, S.A.; Vulpetti, A.; Rogel, O. Pyrrolidine derivatives and their use as complement pathway modulators., W.O. 2014002054A1. 2014.
[37]
Hommel, U.; Lorthiosis, E.L.J.; Maibaum, J.K.; Ostermann, N.; Randl, S.A.; Simic, O.; Vulpetti, A.; Rogel, O. Pyrrolidine derivatives and their use as complement pathway modulators, W.O. 2014002057A1. 2014.
[38]
Altmann, E.; Hommel, U.; Lorthiosis, E.L.J.; Maibaum, J.K.; Ostermann, N.; Quancard, J.; Randl, S.A.; Vulpetti, A.; Flohr, S.; Rogel, O. Complememt pathway modulators and uses thereof., W.O. 2014002058A2. 2014.
[39]
Towler, C.; Altman, E.; Hommel, U.; Lorthiosis, E.L.J.; Maibaum, J.K.; Ostermann, N.; Quancard, J.; Randl, S.A.; Simic, O.; Vulpetti, A. Cyrstalline forms of 1-(2- ((1R,3S,5R)-3-((R)-1-(3-chloro-2-fluorophenyl)ethyl) carbamolyl)- 2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazol[ 3,4-c]pyridine-3-carboxamide.., W.O. 20140020-59A1. 2014.
[40]
Towler, C.; Altmann, E.; Hommel, U.; Lorthiosis, E.L.J.; Maibaum, J.K.; Ostermann, N.; Quancard, J.; Randl, S.A.; Simic, O.; Vulpetti, A. Cyrstalline forms of L-(2- ((LR,3S,5R)-3-(2-Fluoro-3-trifluodomethoxy) phenyl_ carbamoyl) -2 azabicycle O [3.1.0] hexan-2-yl-oxoethyl) -5 - methyl-1H-pyrazolo [3,4-C] pyridine -3- carboxamide and salts thereof. W.O. 2014005150A1. 2014.
[41]
Maibaum, J.; Liao, S.M.; Vulpetti, A.; Ostermann, N.; Randl, S.; Rüdisser, S.; Lorthiois, E.; Erbel, P.; Kinzel, B.; Kolb, F.A.; Barbieri, S.; Wagner, J.; Durand, C.; Fettis, K.; Dussauge, S.; Hughes, N.; Delgado, O.; Hommel, U.; Gould, T.; Mac Sweeney, A.; Gerhartz, B.; Cumin, F.; Flohr, S.; Schubart, A.; Jaffee, B.; Harrison, R.; Risitano, A.M.; Eder, J.; Anderson, K. Small-molecule factor D inhibitors targeting the alternative complement pathway. Nat. Chem. Biol., 2016, 12(12), 1105-1110.
[http://dx.doi.org/10.1038/nchembio.2208] [PMID: 27775713]
[42]
Vulpetti, A.; Randl, S.; Rüdisser, S.; Ostermann, N.; Erbel, P.; Mac Sweeney, A.; Zoller, T.; Salem, B.; Gerhartz, B.; Cumin, F.; Hommel, U.; Dalvit, C.; Lorthiois, E.; Maibaum, J. Structure-based library design and fragment screening for the identification of reversible complement factor D protease inhibitors. J. Med. Chem., 2017, 60(5), 1946-1958.
[http://dx.doi.org/10.1021/acs.jmedchem.6b01684] [PMID: 28157311]
[43]
Hommel, U.; Lorthiosis, E.L.J.; Maibaum, J.K.; Ostermann, N.; Randl, S.A.; Vulpetti, A.; Rogel, O. Complement pathway modulators and used thereof., W.O. 2014009833A2. 2014.
[44]
Lorthiois, E.; Anderson, K.; Vulpetti, A.; Rogel, O.; Cumin, F.; Ostermann, N.; Steinbacher, S.; Mac Sweeney, A.; Delgado, O.; Liao, S.M.; Randl, S.; Rüdisser, S.; Dussauge, S.; Fettis, K.; Kieffer, L.; de Erkenez, A.; Yang, L.; Hartwieg, C.; Argikar, U.A.; La Bonte, L.R.; Newton, R.; Kansara, V.; Flohr, S.; Hommel, U.; Jaffee, B.; Maibaum, J. Discovery of highly potent and selective small-molecule reversible factor D inhibitors demonstrating alternative complement pathway inhibition in vivo. J. Med. Chem., 2017, 60(13), 5717-5735.
[http://dx.doi.org/10.1021/acs.jmedchem.7b00425] [PMID: 28621538]
[45]
Yuan, X.; Gavriilaki, E.; Thanassi, J.A.; Yang, G.; Baines, A.C.; Podos, S.D.; Huang, Y.; Huang, M.; Brodsky, R.A. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica, 2017, 102(3), 466-475.
[http://dx.doi.org/10.3324/haematol.2016.153312] [PMID: 27810992]
[46]
Konar, M.; Granoff, D.M. Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults. Blood, 2017, 130(7), 891-899.
[http://dx.doi.org/10.1182/blood-2017-05-781450] [PMID: 28630122]
[47]
Yang, C.Y.; Phillips, J.G.; Stuckey, J.A.; Bai, L.; Sun, H.; Delproposto, J.; Brown, W.C.; Chinnaswamy, K. Buried hydrogen bond interactions contribute to the high potency of complement factor D inhibitors. ACS Med. Chem. Lett., 2016, 7(12), 1092-1096.
[http://dx.doi.org/10.1021/acsmedchemlett.6b00299] [PMID: 27994744]
[48]
McDonald, A.; Qian, S. Therapeutic inhibitory compounds, W.O. 2017098328A2. 2017.
[49]
Kotian, P.L.; Babu, Y.S; Zhang, W.; Vogeti, L.; Wu, M.; Chintareddy, V.R.; Raman, K. Benzopyrazole compounds and analogues thereof., W.O. 2017136395A1. 2017.
[50]
McDonald, A; Qian, S. Therapeutic inhibitory compounds, W.O. 2018015818A2. 2018.
[51]
Belanger, D.B.; Flohr, S.; Gelin, C.F.; Jendza, K. Aminomethyl-biaryl derivatives complement factor D inhibi-tors and uses thereof.W.O. 2015009977A1. 2015.
[52]
Belanger, D.; Flohr, S.; Gelin, C.F.; Jendza, K.; Ji, N.; Karki, R.G.; Liu, D.; Lorthiois, E.L.J.; Mainolfi, N.; Powers, J.J.; Vulpetti, A. Amidomethyl-biaryl derivatives complement factor D inhibi-tors and uses thereof., W.O.2016088082A1. 2016.
[53]
McGeer, P.L.; Lee, M.; McGeer, E.G. Acetyl salicyclic acid dimers sythesis thereof, and uses there-of to prevent and treat complement-mediated disorders., W.O.2015070354A1,. 2015.
[54]
Lee, M.; Wathier, M.; Love, J.A.; McGeer, E.; McGeer, P.L. Inhibition of aberrant complement activation by a dimer of acetylsalicylic acid. Neurobiol. Aging, 2015, 36(10), 2748-2756.
[http://dx.doi.org/10.1016/j.neurobiolaging.2015.06.018] [PMID: 26248865]
[55]
Ellis-Pegler, R.; Schwabe, C.; Ajari, I.; Robison, H.; Sorensen, R.; Lahey, J.; Yang, W.; Huang, M.; Hui, J.; Kocinsky, H.; Geffner, M.; Apelian, D. An orally administered small molecule factor D inhibitor (ACH-4471) for treatment of PNH and complement diseases: preliminary phase 1 results in healthy volunteers. European Hematology Association 21st Congress, Copenhhagen, Abstract EHA-4145,, 2016, 101>-416.
[56]
Patel, D.; Thanassi, J.A.; Guangwei, Y.; Xuan, Y.; Brodsky, R.A.; Mingjun, H.; Podos, S.D. In vitro combination studies of ACH-4471 with eculizumab to assess a potential “Switch” treatment approach for paroxysmal nocturnal hemoglobinuria. American Society of Hematology 59th Annual Meeting and Exposition, Altanta,, GA2017.
[57]
Späth-Schwalbe, E.; Schrezenmeier, H.; Heimpel, S.H. [Paroxysmal nocturnal hemoglobinuria. Clinical experiences with 40 patients at one center over 25 years] Dtsch. Med. Wochenschr., 1995, 120(30), 1027-1033.
[PMID: 7628314]
[58]
Schubert, J.; Röth, A. Update on paroxysmal nocturnal haemoglobinuria: on the long way to understand the principles of the disease. Eur. J. Haematol., 2015, 94(6), 464-473.
[http://dx.doi.org/10.1111/ejh.12520] [PMID: 25702878]
[59]
Hill, A.; Rother, R.P.; Arnold, L.; Kelly, R.; Cullen, M.J.; Richards, S.J.; Hillmen, P. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica, 2010, 95(4), 567-573.
[http://dx.doi.org/10.3324/haematol.2009.007229] [PMID: 20145265]
[60]
Rondelli, T.; Risitano, A.M.; Peffault de Latour, R.; Sica, M.; Peruzzi, B.; Ricci, P.; Barcellini, W.; Iori, A.P.; Boschetti, C.; Valle, V.; Frémeaux-Bacchi, V.; De Angioletti, M.; Socie, G.; Luzzatto, L.; Notaro, R. Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Haematologica, 2014, 99(2), 262-266.
[http://dx.doi.org/10.3324/haematol.2013.090001] [PMID: 24038027]
[61]
Nishimura, J.; Yamamoto, M.; Hayashi, S.; Ohyashiki, K.; Ando, K.; Brodsky, A.L.; Noji, H.; Kitamura, K.; Eto, T.; Takahashi, T.; Masuko, M.; Matsumoto, T.; Wano, Y.; Shichishima, T.; Shibayama, H.; Hase, M.; Li, L.; Johnson, K.; Lazarowski, A.; Tamburini, P.; Inazawa, J.; Kinoshita, T.; Kanakura, Y. Genetic variants in C5 and poor response to eculizumab. N. Engl. J. Med., 2014, 370(7), 632-639.
[http://dx.doi.org/10.1056/NEJMoa1311084] [PMID: 24521109]
[62]
Achillion Press Release. Available at:http://ir.achillion.com/releasedetail.cfm?ReleaseID=1036547 (Accessed, March 31, 2018)
[63]
Figueroa, J.E.; Densen, P. Infectious diseases associated with complement deficiencies. Clin. Microbiol. Rev., 1991, 4(3), 359-395.
[http://dx.doi.org/10.1128/CMR.4.3.359] [PMID: 1889047]
[64]
Audemard-Verger, A.; Descloux, E.; Ponard, D.; Deroux, A.; Fantin, B.; Fieschi, C.; John, M.; Bouldouyre, A.; Karkowsi, L.; Moulis, G.; Auvinet, H.; Valla, F.; Lechiche, C.; Davido, B.; Martinot, M.; Biron, C.; Lucht, F.; Asseray, N.; Froissart, A.; Buzelé, R.; Perlat, A.; Boutboul, D.; Fremeaux-Bacchi, V.; Isnard, S.; Bienvenu, B. Infections revealing complement deficiency in adults: a French nationwide study enrolling 41 patients. Medicine (Baltimore), 2016, 95(19) e3548
[http://dx.doi.org/10.1097/MD.0000000000003548] [PMID: 27175654]
[65]
Figueroa, J.; Andreoni, J.; Densen, P. Complement deficiency states and meningococcal disease. Immunol. Res., 1993, 12(3), 295-311.
[http://dx.doi.org/10.1007/BF02918259] [PMID: 8288947]
[66]
Sng, C.C.T.; O’Byrne, S.; Prigozhin, D.M.; Bauer, M.R.; Harvey, J.C.; Ruhle, M.; Challis, B.G.; Lear, S.; Roberts, L.D.; Workman, S.; Janowitz, T.; Magiera, L.; Doffinger, R.; Buckland, M.S.; Jodrell, D.J.; Semple, R.K.; Wilson, T.J.; Modis, Y.; Thaventhiran, J.E.D. A type III complement factor D deficiency: Structural insights for inhibition of the alternative pathway. J. Allergy Clin. Immunol., 2018, 142(1), 311-314.e6.
[http://dx.doi.org/10.1016/j.jaci.2018.01.048] [PMID: 29522842]
[67]
Hiemstra, P.S.; Langeler, E.; Compier, B.; Keepers, Y.; Leijh, P.C.; van den Barselaar, M.T.; Overbosch, D.; Daha, M.R. Complete and partial deficiencies of complement factor D in a Dutch family. J. Clin. Invest., 1989, 84(6), 1957-1961.
[http://dx.doi.org/10.1172/JCI114384] [PMID: 2687330]
[68]
Weiss, S.J.; Ahmed, A.E.; Bonagura, V.R. Complement factor D deficiency in an infant first seen with pneumococcal neonatal sepsis. J. Allergy Clin. Immunol., 1998, 102(6 Pt 1), 1043-1044.
[http://dx.doi.org/10.1016/S0091-6749(98)70346-X] [PMID: 9847449]
[69]
Biesma, D.H.; Hannema, A.J.; van Velzen-Blad, H.; Mulder, L.; van Zwieten, R.; Kluijt, I.; Roos, D. A family with complement factor D deficiency. J. Clin. Invest., 2001, 108(2), 233-240.
[http://dx.doi.org/10.1172/JCI200112023] [PMID: 11457876]
[70]
Sprong, T.; Roos, D.; Weemaes, C.; Neeleman, C.; Geesing, C.L.; Mollnes, T.E.; van Deuren, M. Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. Blood, 2006, 107(12), 4865-4870.
[http://dx.doi.org/10.1182/blood-2005-07-2820] [PMID: 16527897]
[71]
Kluin-Nelemans, H.C.; van Velzen-Blad, H.; van Helden, H.P.; Daha, M.R. Functional deficiency of complement factor D in a monozygous twin. Clin. Exp. Immunol., 1984, 58(3), 724-730.
[PMID: 6568950]
[72]
Rother, R.P.; Rollins, S.A.; Mojcik, C.F.; Brodsky, R.A.; Bell, L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol., 2007, 25(11), 1256-1264.
[http://dx.doi.org/10.1038/nbt1344] [PMID: 17989688]
[73]
Zhao, Y.; Galvan, M.D.; Podos, S.D.; Thanassi, J.A.; Yang, G.; Patel, D.; Fabrycki, J.; Luu, A.; Yang, W.; Wiles, J.; Phadke, A.; Barrish, J.; Huang, M. Assessment of complement-mediated bactria killing and effect of a small molecule factor D on the killing in vitro. XXVI International Complement Workshop, Kanazawa, Japan2016, pp. 4-8.

Rights & Permissions Print Cite
Article Metrics
226
19
World Chagas Disease
© 2024 Bentham Science Publishers | Privacy Policy